Cancer Targeted Technology (CTT)

Cancer Targeted Technology (CTT) is a biotechnology company that designs and patents small molecule drugs for the diagnosis and treatment of cancer. The company utilizes a proprietary peptidomimetic targeting scaffold that binds irreversibly to Prostate-Specific Membrane Antigen (PSMA), a biomarker highly expressed on prostate tumor cells and the blood vessels of various solid tumors. By leveraging this unique binding mechanism, CTT’s agents are rapidly internalized by tumor cells, allowing for the precise, site-specific delivery of diagnostic imaging agents and therapeutic payloads. Its current clinical and development pipeline includes CTT1057, a PET imaging agent, as well as radiotherapeutic and chemotherapeutic candidates like CTT1403 and CTT2274.

These advancements aim to improve patient outcomes by providing more accurate disease detection, staging, and monitoring, while minimizing the side effects associated with systemic treatments. By targeting PSMA, which is expressed in more than 90% of prostate cancers and frequently found in other solid tumors such as lung, renal, and pancreatic cancers, CTT seeks to address significant clinical needs in oncology. The company’s platform approach is supported by various research grants and strategic industry partnerships, enabling the development of targeted solutions intended to improve both survival rates and the quality of life for patients.